Ocular Therapeutix (OCUL) Misses Q4 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Ocular Therapeutix (OCUL) Misses Q4 EPS by 4c

Ocular Therapeutix™ Reports Fourth Quarter and Year End 2018 Financial Results and Business Update

March 7, 2019 4:01 PM EST

DEXTENZA® Commercial Launch Planned for Mid-Year 2019

OTX-TP Phase 3 Data Expected in the First Half of 2019

Strengthened Cash Position with Closing of $37.5 Million Financing

BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the fourth quarter and year ended December 31, 2018 and provided a business update.

2018 was a transformational year for Ocular highlighted by the U.S. Food and... More